Download PDF
Thromb Haemost 2002; 88(02): 362-364
DOI: 10.1055/s-0037-1613214
Letters to the Editor
Schattauer GmbH

A 4% Solution of Bovine Serum Albumin May Be Used in Place of Factor VIII:C Deficient Plasma in the Control Sample in the Nijmegen Modification of the Bethesda Factor VIII:C Inhibitor Assay

Bert Verbruggen
1   Central Laboratory for Haematology, University Medical Centre St Radboud Nijmegen, The Netherlands
,
Waander van Heerde
1   Central Laboratory for Haematology, University Medical Centre St Radboud Nijmegen, The Netherlands
,
Irena Novákovà
2   Department of Haematology, University Medical Centre St Radboud Nijmegen, The Netherlands
,
David Lillicrap
3   Kingston General Hospital & Queen’s University, Kingston, Ontario, Canada
,
Alan Giles
3   Kingston General Hospital & Queen’s University, Kingston, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 06 March 2002

Accepted 22 April 2002

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Bert Verbruggen, Irena Novakova, Hans Wessels, Jan Boezeman, Marijke van den Berg, Eveline Mauser-Bunschoten. The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability. Thromb Haemost 1995; 73: 247-51.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Giles AR, Verbruggen B, Rivard G, Teitel J, Walker I. A detailed comparison of the performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Hemophilia A Population of Canada. Thromb Haemost 1998; 79: 872-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Bert Verbruggen, Alan Giles, John Samis, Kitty Verbeek, Ewald Mensink, Irena Novákovà. The Type of Factor VIII Deficient Plasma used influences the performance of the Nijmegen Modification of the Bethesda Assay for Factor VIII Inhibitors. Thromb Haemost 2001; 86: 1435-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Van den Brink EN, Turenhout EAM, Davies J, Bovenschen N, Fijnvandraat K, Ouwehand WH, Peters M, Voorberg J. Human Antibodies with Specificity for the C2 domain of factor VIII are derived from germline genes. Blood 2000; 95: 558-63.
    PubMedGoogle Scholar